Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Changzhou SPL is a specialized manufacturer of heparin-based active pharmaceutical ingredients (APIs) and other naturally derived proteins. As a subsidiary of Scientific Protein Laboratories (SPL) and part of the Shenzhen Hepalink Pharmaceutical Group, the company operates a large-scale, GMP-compliant facility in Changzhou, China. Its primary focus is the production of high-purity heparin sodium and heparin calcium derived from porcine sources for the global pharmaceutical market. The company plays a vital role in the anticoagulant supply chain, ensuring the availability of critical life-saving medications for cardiovascular and surgical applications. In addition to heparin, Changzhou SPL produces pancreatin and other protein-based products, maintaining rigorous quality standards required by international regulatory bodies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Changzhou SPL.